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652C-reactive protein and brain natriuretic peptide as
predictors of adverse events after lower extremity
endovascular revascularization
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Stephanie N. Thompson, PhD,b Molly John, MD,c James R. Campbell, MD,a and
Ali F. AbuRahma, MD,a Charleston, WVa
Background: High-sensitivity C-reactive protein (hsCRP) and brain natriuretic peptide (BNP) have been shown to be
independent predictors of adverse cardiovascular outcomes and increased risk of secondary interventions or limb loss in
patients with peripheral arterial disease (PAD). To assist clinicians in decision-making about treatment approaches and
predicting postprocedure mortality and morbidity, we retrospectively examined patients with preprocedure hsCRP and
BNP levels who underwent elective angioplasty or stent placement for lower extremity PAD.
Methods: The study period was from January 1, 2007, to December 31, 2012, and patients were included who had an-
gioplasty or stenting for PAD. Minimal required follow-up for study inclusion was at least one postoperative ankle-
brachial index, contrast angiography, or duplex imaging of the treated limb. Events of interest included major adverse
limb events (MALE), deﬁned as target vessel revascularization, amputation, or disease progression by 1 year, and major
adverse cardiovascular events (MACE; stroke, myocardial infarction, or death) by 2 years. Elevated/abnormal values for
our biomarkers of interest were established by the upper limits of our institution’s clinical laboratory reference range
(hsCRP, >0.80 mg/dL; BNP, >100 pg/mL).
Results: A total of 159 limbs in 118 patients were included in analysis (42% men; median age [range], 64 [42-87] years).
All limbs were symptomatic (Rutherford classiﬁcation: 1-6). Iliac artery revascularization without other adjunct lower
extremity intervention was performed in 60% of the limbs. High hsCRP levels (>0.80 mg/dL) were present in 32 patients
(27%) and high BNP values (>100 pg/mL) in 24 patients (20%). Kaplan-Meier analysis with log-rank comparison
demonstrated that elevated hsCRP levels were associated with MALE but only in limbs receiving interventions distal to
the iliac arteries (P [ .005). High BNP levels did not affect MALE rates (P [ .821). Conversely, both elevated BNP
levels (hazard ratio, 5.6; 95% conﬁdence interval [CI], 2.0-5.8; P [ .001) and hsCRP levels (hazard ratio, 2.9; 95% CI,
1.1-7.6; P[ .034) predicted MACE at 2 years in the presence of confounders in Cox proportional hazards multivariate
analysis. Patients with high preintervention values of hsCRP and BNP were 10.6 times (95% CI, 2.6-42.9; P [ .001)
more likely to experience MACE than were patients with normal hsCRP and BNP values.
Conclusions: After lower extremity endovascular interventions, elevated preprocedural hsCRP levels are associated with
MALE (femoral-popliteal interventions), and elevated levels of hsCRP and BNP are associated with late cardiovascular
events. (J Vasc Surg 2014;60:652-60.)Because atherosclerosis is an inﬂammatory process
involving the walls of the arterial system, a large body of
research exists regarding the utility of inﬂammatory
proteins as biomarkers of peripheral arterial disease
(PAD).1-3 Particular interest has been paid to high-
sensitivity C-reactive protein (hsCRP), a marker of early
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://dx.doi.org/10.1016/j.jvs.2014.03.254PAD in the absence of cardiovascular disease, diabetes, or
hypertension.4,5 The hsCRP levels also carry predictive
value for endovascular treatment of PAD. Elevated prein-
tervention hsCRP has been shown to predict restenosis
after below-knee percutaneous angioplasty,6 the need
for reintervention, index limb amputation, and all-cause
mortality in patients after endovascular therapy (EVT)
for PAD.7-9
Brain natriuretic peptide (BNP) is a well-characterized
hormone important in ﬂuid and blood pressure regula-
tion.10 BNP is also elevated in patients with PAD, which
is likely due to the correlation between PAD and ischemic
heart disease.11 Data have also shown that PAD patients
with elevated BNP have increased all-cause mortality.12
Studies also demonstrate that elevated preoperative BNP
in patients undergoing aortic aneurysm repair, carotid
endarterectomy, and peripheral vein bypass correlates
with increased risk for postoperative cardiac events
including nonfatal myocardial infarction and cardiovascular
death.13,14 However, the predictive value of BNP in PAD
patients undergoing EVT remains unknown.
Table I. International Classiﬁcation of Diseases, Ninth
Revision (ICD-9) diagnosis and procedure codes used to
identify patients receiving endovascular therapy (EVT)
for peripheral arterial disease (PAD)
Code Description
PAD ICD-9 diagnosis codes
250.7 Diabetes with peripheral circulatory disorders
440.2X Atherosclerosis of native arteries of extremities
440.3x Atherosclerosis of extremities of unspeciﬁed graft
440.4 Chronic total occlusion of artery of the extremities
443.9 Peripheral vascular disease, unspeciﬁed
444.22 Arterial embolism and thrombosis of lower extremity
in combination with
Endovascular ICD-9 procedure codes
39.50 Angioplasty or atherectomy of other non-coronary
vessel(s)
39.90 Insertion of non-drug-eluting peripheral vessel stent(s)
00.55 Insertion of drug-eluting peripheral vessel stent(s)
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BNP are independent predictors of adverse events in
PAD patients, the two have not been studied together after
EVT. Therefore, we retrospectively examined the relation-
ship between preintervention hsCRP and BNP levels and
the occurrence of adverse events in a cohort of patients
who underwent elective angioplasty or stent placement
for lower extremity PAD. By doing this, we hope to pro-
vide clinicians with additional tools to predict perioperative
mortality and morbidity and to guide decisions about treat-
ment approaches and postintervention surveillance after
EVT for PAD.
METHODS
We retrospectively examined patients who underwent
elective EVT in the lower extremities by the primary author
(P.A.S.) at Charleston Area Medical Center (CAMC),
Charleston, West Virginia, between January 1, 2007, and
December 31, 2012. The sample was identiﬁed by use of
International Classiﬁcation of Diseases, Ninth Revision
(ICD-9) diagnostic codes for PAD in combination with
ICD-9 procedure codes for EVT (Table I). Inclusion
criteria included the presence of preintervention hsCRP
and BNP levels obtained within 30 days before the proce-
dure per standard protocol of the admitting physician
(P.A.S.), elective EVT including angioplasty or stent place-
ment, and at least one postoperative follow-up consisting
of one or more of the following: duplex ultrasound exam-
ination, conventional contrast angiography, or ankle-
brachial index (ABI) measurements. Exclusion criteria
included patients younger than 18 years, emergency lower
limb revascularization, lack of hsCRP or BNP levels before
the procedure, lack of postoperative follow-up (ABI, angi-
ography, or duplex ultrasound), and patients with concom-
itant procedures to treat arterial aneurysms. All aspects of
the study were reviewed and approved by the CAMC/
West Virginia University, Charleston Division, Institutional
Review Board.Our two primary outcomes of interest included major
adverse limb events (MALE) and major adverse cardio-
vascular events (MACE). We deﬁned MALE as the
composite end point encompassing target vessel revascu-
larization (TVR), limb amputation, or disease progression
by 12 months after the procedure. Disease progression
was deﬁned as the total occlusion of the treated vessel
as determined by angiography or duplex ultrasound or a
greater than 0.15 decrease in ABI in the treated
limb.15,16 MACE was the composite end point composed
of stroke, myocardial infarction, and death occurring by
2 years after the procedure. Secondary end points
included the individual components of the two primary
end points. Follow-up for MALE continued from the
time of the procedure until an event or the most recent
angiography, duplex ultrasound, or ABI measurement
(mean follow-up, 15 6 12 months). Follow-up for
MACE continued from the time of the procedure until
the occurrence of an event or the most recent admission
or visit at CAMC or an afﬁliated clinic or ofﬁce (mean
follow-up, 30 6 17 months).
Collected demographic data and health history evalua-
tion included age, gender, race, body mass index, and cur-
rent tobacco use. Comorbidity evaluation included obesity
(body mass index >30), diabetes mellitus, hypertension,
hyperlipidemia, coronary artery disease, chronic kidney dis-
ease, and heart failure. Recent events or conditions, with
recent deﬁned as occurring within 30 days before the pro-
cedure, that can induce a systemic inﬂammation response
were examined and included the following: trauma or
illness; recurring hospitalization; and the occurrence of
stroke, transit ischemic attack, myocardial infarction, or
liver failure. Preprocedure clinical data evaluated included
ABI, home medication, history of prior vascular interven-
tion, Rutherford classiﬁcation of lower extremity ischemia,
and laboratory values for hsCRP and BNP. The hsCRP
level was measured by immunometric assay, with detection
in the lower limit of 0.02 mg/dL and the upper limit of
10.0 mg/dL. Levels of BNP were measured by two-site
sandwich immunoassay. Elevated/abnormal values for
our biomarkers of interest were established by the upper
limit of our institution’s clinical laboratory reference range
(high hsCRP, >0.80 mg/dL; high BNP, >100 pg/mL).
In addition, information on the vessel treated, the presence
of occlusion, whether the procedure was TVR, the type
and number of stents, and the length of stent required
were included in data collection. All-cause mortality after
discharge was determined by the Social Security Death
Index.
Data analysis. SPSS version 19.0 was used for data
analysis. Descriptive statistics included frequencies and
percentages for categorical variables; means 6 standard
deviations were used for continuous variables, except for
age, for which median [range] was used. Univariate analysis
to determine differences between groups (elevated vs
normal preprocedure biomarker levels) for patient and
limb characteristics was performed by c2 analysis (Fisher
exact test when appropriate) for categorical data and
Table II. Patient demographics as a function of elevated high-sensitivity C-reactive protein (hsCRP) or brain natriuretic
peptide (BNP) levels
hsCRP BNP
Normal #0.80
mg/dL (n ¼ 86)
Abnormal/high >0.80
mg/dL (n ¼ 32) P
Normal #100
pg/mL (n ¼ 94)
Abnormal/high >100
pg/mL (n ¼ 24) P
Male gender 44% 37% .538 48% 2% .031
Median age, years (range) 63 (42-87) 65 (45-83) .670 61 (42-87) 69 (51-87) .001
Nonwhite 4% 0% .562 3% 0% 1.000
Obesity 28% 38% .435 34% 17% .161
Current tobacco use 57% 53% .868 61% 38% .071
Diabetes mellitus 41% 44% .929 44% 33% .496
Hypertension 85% 94% .350 86% 92% .733
Hyperlipidemia 65% 72% .636 64% 79% .237
Coronary artery disease 54% 59% .716 49% 79% .015
Chronic kidney disease 11% 16% .523 7% 29% .008
Heart failure 5% 3% 1.000 5% 0% .582
Statin on admission 63% 50% .295 57% 67% .557
Bold entries indicate statistical signiﬁcance.
Table III. Limb and procedural characteristics presented as a function of high-sensitivity C-reactive protein (hsCRP) or
brain natriuretic peptide (BNP) levels
Total
hsCRP BNP
Normal #0.80
mg/dL (n ¼ 115)
Abnormal/high >0.80
mg/dL (n ¼ 44) P
Normal #100
pg/mL (n ¼ 124)
Abnormal/high >100
pg/mL (n ¼ 35) P
Indication for EVT
Claudication 84% 88% 73% .039 86% 74% .151
Critical limb ischemia 16% 12% 27% 14% 26%
Treated lesion location
Iliac arteries only 60% 60% 61% 1.00 62% 54% .523
SFA, popliteal, tibial, or bypass 40% 40% 39% 38% 46%
Vessel occluded 36% 33% 43% .314 34% 43% .436
Stent use 84% 87% 75% .113 85% 80% .688
EVT, Endovascular therapy; SFA, superﬁcial femoral artery.
Bold entries indicate statistical signiﬁcance.
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MALE was analyzed on a per limb basis, whereas MACE
was analyzed per patient. Kaplan-Meier curves with log-
rank analysis were used to examine differences in time to
events. We used univariate and multivariate Cox propor-
tional hazards regression analyses to examine the relation-
ship of risk factors, including elevated hsCRP and BNP
levels, with the adverse outcomes of MALE and MACE.
Criterion for inclusion in the multivariate model was a
univariate analysis value of P < .10, with forward stepwise
regression entry employed. A P level < .05 was considered
statistically signiﬁcant.
RESULTS
A total of 163 patients having hsCRP and BNP testing
before lower extremity EVT were identiﬁed. On chart
review, 45 patients were excluded (14 for lacking
follow-up, 12 for concomitant open vascular procedures,
12 for procedures outside the lower extremities, six for
concomitant abdominal aortic procedures, and one
patient for having an emergent procedure to treat acutelimb ischemia). A total of 159 limbs in 118 patients un-
dergoing endovascular interventions to the iliac or lower
extremity arteries served as our study cohort. The study
comprised 50 men and 68 women with a median age
[range] of 64 [42-87] years. One patient had an
inﬂammation-inducing event (myocardial infarction) in
the 30 days previous to EVT. No other patients had a
trauma or illness requiring hospitalization or an
inﬂammation-inducing event in the 30 days before the
procedure. The mean level of hsCRP in our study cohort
was 0.98 6 1.54 mg/dL, with elevated hsCRP levels
(>0.80 mg/dL) present in 32 patients (27.1%). The
mean level of BNP was 90.2 6 133.4 pg/mL, with
high BNP values (>100 pg/mL) in 24 patients (20.3%).
Patient demographics are presented in Table II as a func-
tion of elevated hsCRP and BNP levels.
All limbs were symptomatic and were categorized into
clinical stages of PAD according to the Rutherford classiﬁ-
cation. A total of 133 limbs (84%) had reported claudica-
tion (Rutherford stages 1-3) and 26 (16.4%) had critical
limb ischemia, with 17 limbs (11%) having rest pain
Fig 1. A, Kaplan-Meier curve showing event-free survival from
major adverse limb event (MALE) at 1 year in limbs categorized by
preprocedure levels of high-sensitivity C-reactive protein (hsCRP).
B, Kaplan-Meier curve showing event-free survival at 1 year from
MALE in limbs categorized by preprocedure levels of brain
natriuretic peptide (BNP).
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 3 Stone et al 655(Rutherford stage 4) and nine limbs (6%) having tissue loss
or ulceration (Rutherford stage 5-6). The distribution of
vessels with treated lesions was iliac arteries in 111 limbs
(70%), femoropopliteal artery in 58 limbs (37%), tibial/
below-the-knee interventions in six limbs (4%), and previ-
ously placed bypass grafts in six limbs (4%), with 22 limbs
(14%) having more than one vessel treated. A total of 96
limbs (60%) received EVT in the iliac region without
concomitant procedures to distal arteries. The type of
intervention consisted of angioplasty without stenting in
26 limbs (16%) and angioplasty with stenting in 133 limbs(84%). Intervention was performed secondary to occlusion
in 57 limbs (35.8%). One stent was placed in 85 limbs
(53.5%), with more than one stent required in 48 limbs
(30%). In the 133 limbs receiving stents, bare metal stents
were used in 118 limbs (89%), covered stents in three
limbs (2%), and drug-eluting stents in 12 limbs (9%).
Mean stent length was 101.2 6 100.6 mm (range, 20-
430 mm). Limb and procedural characteristics are pre-
sented as a function of elevated hsCRP and BNP levels
in Table III.
After endovascular intervention, the event-free sur-
vival rates from MALE were 91% at 6 months and 80%
at 12 months. Kaplan-Meier analysis with log-rank analysis
demonstrated that elevated hsCRP levels were not associ-
ated with MALE (P ¼ .127; Fig 1, A). However, when
limbs that received EVT distal to the iliac arteries (n ¼
63) were examined independently, hsCRP levels
>0.80 mg/dL had signiﬁcantly elevated rates of MALE
compared with normal hsCRP levels (P ¼ .005). There
was no effect of elevated hsCRP levels on MALE in limbs
with iliac arteries treated only (P ¼ .438). High BNP
levels (>100 pg/mL) were not associated with MALE
in noniliac (P ¼ .343) or iliac (P ¼ .806) revasculariza-
tions or in all treated limbs (P ¼ .822; Fig 1, B). No limbs
underwent amputation within 12 months of the proce-
dure. However, 19 limbs required TVR (14 endovascular,
ﬁve surgical reinterventions) within the initial year after
the procedure. High hsCRP levels were associated with
the need for TVR (P ¼ .048), whereas elevated BNP
levels were not associated (P ¼ .633; Table IV). Neither
hsCRP nor BNP elevated levels predicted MALE in uni-
variate Cox proportional hazards analyses (hsCRP: hazard
ratio [HR], 1.9; 95% conﬁdence interval [CI], 0.8-4.2;
P ¼ .134; and BNP: HR, 0.9; 95% CI, 0.3-2.4; P ¼
.823),with P values above the .10 threshold for inclusion
in the multivariate analysis as described in the Methods
section. Thus, multivariate analysis for predictors for
MALE is not presented.
The rates of freedom from MACE in our patient sam-
ple at 12 months and 24 months were 92% and 81%,
respectively. MACE events occurring in the 2-year period
are presented in Table V. Patients with high hsCRP
trended toward having decreased freedom from MACE
(68% vs 86%), but the difference failed to meet statistical
signiﬁcance (P ¼ .053) as shown in Fig 2, A. Conversely,
elevated BNP values were associated with decreased
event-free rates from MACE (P ¼ .015), with a rate of
64% vs 86% in patients with normal BNP levels
(Fig 2, B). In univariate Cox proportional hazards ana-
lyses, elevated BNP levels predicted MACE at 2 years
(HR, 3.1; 95% CI, 1.2-8.0; P ¼ .021), whereas high
hsCRP values trended toward but failed to reach statisti-
cal signiﬁcance for predicting MACE (HR, 2.4; 95% CI,
1.0-6.1; P ¼ .061). Multivariate analysis demonstrated
that both elevated BNP and hsCRP levels predicted
MACE in the presence of confounders (BNP: HR, 5.6;
95% CI, 2.0-15.8; P ¼ .001; and hsCRP: HR, 2.9; 95%
CI, 1.1-7.6; P ¼ .034; Table VI).
Table IV. Major adverse limb events (MALE) occurring in the initial year after the procedure
hsCRP BNP
Normal #0.80
mg/dL (n ¼ 115)
Abnormal/high >0.80
mg/dL (n ¼ 44) P
Normal #100
pg/mL (n ¼ 124)
Abnormal/high >100
pg/mL (n ¼ 35) P
One year free from
TVR 88% 71% .048 85% 81% .557
Amputation 100% 100% d 100% 100% d
Disease progression 84% 74% .337 82% 81% .924
BNP, Brain natriuretic peptide; hsCRP, high-sensitivity C-reactive protein; TVR, target vessel revascularization.
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combination, we found that having elevated preinterven-
tion levels of both hsCRP and BNP did not predict
MALE at 1 year (HR, 2.0; 95% CI, 0.4-8.7; P ¼ .377)
in comparison to those with normal biomarker levels
(Fig 3, A). However, patients having both elevated
hsCRP and BNP values were 10.6 times (95% CI, 2.6-
42.9; P ¼ .001) more likely to experience the adverse
outcome of MACE within 2 years of the procedure in
comparison to patients with normal hsCRP and BNP
values (Fig 3, B).
DISCUSSION
Biochemical markers assist in the diagnosis and man-
agement of vascular patients. D-dimer levels are used to
help determine risk of deep venous thrombosis and in
some settings have eliminated the need for duplex ultra-
sound examinations on the basis of the biomarker’s
high negative predictive value. Postoperatively, troponin
levels aid in identifying patients with non-ST myocardial
infarctions. BNP has been used to quantify degrees of
heart failure and as a predictor for long-term mortality.17
In the cardiac literature, preprocedural hsCRP levels have
been associated with an increased risk of coronary reste-
nosis after intervention. Buffon et al,18 more than a
decade ago, reported more than twice the incidence of
clinical coronary restenosis at 1 year after angioplasty in
patients with elevated levels of preprocedural hsCRP vs
those possessing levels within the reference range.
Aligned with the Achilles’ heel of peripheral revasculariza-
tion (ie, development of recurrent restenosis or progres-
sion of disease), elevated hsCRP has been associated
with increased risk of amputation or reintervention of
the treated limb.8,9 Thus, we believe that if preprocedure
biochemical markers in endovascular interventions for
PAD predict future limb-related complications and late
cardiovascular events, the information may improve out-
comes by directing aggressive secondary prevention in pa-
tients with high markers.
In our current study, the patient cohort included those
receiving elective iliac, femoropopliteal, or tibial interven-
tions during a 6-year period performed by a single practi-
tioner. The majority of lesions treated were in the iliac
territory, and elevated hsCRP levels were not associated
with an increased risk of repeated intervention orsubsequent ipsilateral limb loss. However, in limbs treated
below the inguinal ligament, high hsCRP levels revealed an
increased risk of secondary procedures or intervention fail-
ure. This is comparable to the results of Ishii et al,9 who
evaluated the risk of secondary interventions and major
amputation by quartiles of preoperative hsCRP levels and
demonstrated by multivariate analysis that the risk of ipsi-
lateral limb events was related to hsCRP, elevated TransAt-
lantic Inter-Society Consensus lesion class, and presence of
ulcer or gangrene. Similarly, Schillinger et al,19 in evalu-
ating patients with angioplasty of the femoropopliteal
segment, found that baseline CRP levels predicted 12-
month restenosis.
Some major differences between our study and that of
Ischii et al are that their series included a much larger
cohort with 234 patients, nearly twice the sample size of
our group, and all patients in the study of Ischii et al had
end-stage renal disease (ESRD) requiring hemodialysis
compared with <10% of our patients having end-stage
renal disease. In addition, their mean follow-up was longer
at 33 months compared with our mean follow-up of
15 months. It is possible that at a longer follow-up period,
we will be able to demonstrate an increased risk for either
MALE or MACE with elevated hsCRP values for the entire
cohort. Last, our group was composed of lesions predom-
inantly treated in the iliac region, 60% in our patient cohort
compared with 31% in that of Ischii et al, which could
strongly affect results because restenosis and reinterven-
tions are much less common in the iliac arteries compared
with the femoropopliteal segment and tibial arteries. Other
reports examining signiﬁcance of hsCRP in patients with
PAD have focused on the relationship between inﬂamma-
tion and disease progression. Vainas et al20 measured base-
line hsCRP levels and ABI at initial evaluation and
subsequently at 12-month clinical follow-up. Patients
with elevated hsCRP statistically were more likely to
show a reduction in ABI at their 12-month follow-up
compared with those with lower hsCRP values. Further-
more, Owens et al,21 in evaluating prospectively 91 pa-
tients undergoing infrainguinal vein bypass surgery, found
that preoperative elevated hsCRP values showed a strong
correlation with adverse conduit-related and cardiovascular
outcomes.
Plasma BNP levels, on the other hand, have been pri-
marily used as a method to monitor intravascular ﬂuid
Table V. Major adverse cardiovascular events (MACE) occurring in 2 years after the procedure
hsCRP BNP
Normal #0.80
mg/dL (n ¼ 86)
Abnormal/high >0.80
mg/dL (n ¼ 32) P
Normal #100
pg/mL (n ¼ 94)
Abnormal/high >
100 pg/mL (n ¼ 24) P
Two years free from
Myocardial infarction 99% 79% .004 93% 95% .884
Stroke 94% 90% .672 96% 76% .032
All-cause death 94% 82% .030 95% 72% .003
BNP, Brain natriuretic peptide; hsCRP, high-sensitivity C-reactive protein.
Fig 2. A, Kaplan-Meier curve showing event-free survival from
major adverse cardiovascular events (MACE) at 2 years in
patients categorized by preprocedure levels of high-sensitivity
C-reactive protein (hsCRP). B, Kaplan-Meier curve showing
event-free survival from MACE at 2 years in patients catego-
rized by preprocedure levels of brain natriuretic peptide
(BNP).
Table VI. Cox proportional hazards model analysis of
predictors for major adverse cardiovascular events
(MACE)
HR
(95% CI)
P
value
Univariate analysis
Elevated hsCRP (>0.80 mg/dL) 2.4 (1.0-6.2) .061
Elevated BNP (>100 pg/mL) 3.1 (1.2-8.0) .021
Age >65 years 3.3 (1.2-9.3) .023
Male gender 0.8 (0.3-2.0) .613
Obesity (body mass index >30) 1.2 (0.5-3.2) .703
Current tobacco use 1.0 (0.4-2.5) .948
Diabetes mellitus 1.3 (0.5-3.3) .578
Hypertension 2.9 (0.4-21.8) .302
Hyperlipidemia 1.4 (0.5-3.8) .564
Coronary artery disease 3.1 (1.0-9.6) .043
Chronic kidney disease 2.9 (1.0-8.3) .040
Heart failure 8.9 (1.8-43.9) .007
No statin at discharge 2.6 (1.0-6.8) .047
No clopidogrel at discharge 1.4 (0.5-3.6) .541
Multivariate analysisa
Elevated hsCRP 2.9 (1.1-7.6) .034
Elevated BNP 5.6 (2.0-15.8) .001
Heart failure 27 (4.7-157) <.001
No statin at discharge 3.2 (1.2-8.6) .020
BNP, Brain natriuretic peptide; CI, conﬁdence interval; HR, hazard ratio;
hsCRP, high-sensitivity C-reactive protein.
aMultivariate model included variables having P < .10 by univariate analyses
and employed forward stepwise entry.
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as a predictor of adverse events after surgery. In our se-
ries, patients with baseline BNP values above normal
levels demonstrated higher rates of major adverse events,
including mortality during the follow-up period. Limited
published information is available on mortality and
whether BNP values are predictive of outcome for those
undergoing EVT for PAD. BNP has been demonstrated
to be an independent predictor of postoperative myocar-
dial injury in patients undergoing abdominal aortic aneu-
rysm surgery or in patients with subcritical limb
ischemia.22 In addition to perioperative cardiac events,
BNP has been associated with major adverse cardiac
events and mortality for years after major vascular surgery
as demonstrated by the same author in a later publica-
tion23 as well as by others.12-14
The most impressive ﬁnding in our series is the com-
bined effect of an increased hsCRP and BNP on MACE
Fig 3. A, Hazard ratios for major adverse limb event (MALE) at
1 year for preprocedure high-sensitivity C-reactive protein
(hsCRP) levels in combination with brain natriuretic peptide
(BNP) levels. B, Hazard ratios of major adverse cardiovascular
events (MACE) at 2 years for preprocedure hsCRP levels in
combination with BNP levels. High hsCRP equaled levels
>0.80 mg/dL; high BNP equaled levels >100 pg/mL.
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biomarkers poses a 10 times hazard risk compared with in-
dividuals with normal values of both markers. The dramatic
risk in this subset may help further target medical strategies
for those at highest risk for poor long-term survival. Future
studies may look speciﬁcally at statin therapy to lower
hsCRP values in patients with normal lipid proﬁles. This
would include assessing hsCRP before elective endovascu-
lar interventions and maximizing statin medication therapy
to assess improvement in limb outcomes and mortality.
The JUPITER study, with a planned 5-year follow-up, ran-
domized patients with normal low-density lipoprotein and
elevated hsCRP levels (>2.0 mg/L) to either placebo or
rosuvastatin.24 The trial was stopped at <2 years secondary
to outcomes. There were 142 major cardiovascular events
in the treated arm vs 251 in the placebo cohort, resulting
in a 44% reduction of MACE in those medicated. Rosuvas-
tatin reduced hsCRP levels by 37%, but without a control
group with normal hsCRP levels, there was no clear indica-
tion that elevated hsCRP is required for rosuvastatin toprovide a beneﬁt regarding cardiovascular adverse events.
Further research is needed to clarify the role of statins as
a method of reducing hsCRP levels in PAD patients to
improve outcome.
Limitations. The main limitation of the study is that
the sample size was small, and outcomes may have been
affected if a larger sample size were included. The main
example of this was that patients with a high hsCRP
trended toward having decreased freedom from MACE
(68% vs 86%) but failed to meet statistical signiﬁcance
(P ¼ .053). A larger sample size may have resulted in
this demonstrating a statistically signiﬁcant difference.
Last, this was a retrospective study, and only patients
were included who had appropriate follow-up. Further-
more, whereas our vascular practice advocates that patients
follow up with color duplex ultrasound or ABI at 1 and
6 months and then every 12 months after EVT, patient
compliance is imperfect. Patients who are doing well tend
to be less likely to follow up, and this may have affected the
outcomes of the study.
CONCLUSIONS
Biochemical markers in patients undergoing lower ex-
tremity intervention can serve as a predictor of both
limb-related events (femoral-popliteal interventions) and
MACE, especially when hsCRP and BNP are used in
combination.
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Dr Stone and the group fromWest Virginia on an excellent presen-
tation and a well-written manuscript.
As a specialty, despite technical advances, we continue to be
plagued by the poor durability of lower extremity revasculariza-
tion, whether it is percutaneous intervention or vein bypass sur-
gery. There are at least 12 papers at the Southern Association
for Vascular Surgery meeting alone focused on outcomes in pe-
ripheral arterial disease, including talks ranging from emphasizing
patient-centric end points to the effect of race or gender on out-
comes, the role of polymorphisms in the p27kip1 gene and their
effect on cellular regulation and intimal hyperplasia, and even
how an individual’s personality type affects outcomes in
claudication.
Dr Stone and his colleagues have added new knowledge to
this effort by focusing on two common cardiovascular biomarkers,
high-sensitivity C-reactive protein (CRP) and brain natriuretic
peptide (BNP), and their potential to better predict outcomes
and complications after lower extremity intervention. In summary,
they have shown that
d Elevated preintervention levels of CRP may predict a higher
rate of adverse limb events, but the association was limited
only to patients undergoing infrainguinal intervention.
d Elevated levels of BNP were not associated with limb events.
d Elevated levels of both CRP and BNP were independently
associated with higher rates of major adverse cardiac events
(MACE).
d And, perhaps most dramatic, the combination of the two
markers was highly predictive of a 10-fold increase in MACE.I offer the following three questionsdone mechanical, one
strategic, and one philosophical:
1. First, several areas of potential bias exist. The 118 patients
during 6 years equals approximately 20/year. What percent-
age of the total number of patients receiving intervention
during that time frame does this represent, and what degree
of selection bias does this introduce? Also, there was a prepon-
derance of iliac disease and claudication in your cohort, but
the association of CRP to limb events was seen only in the
infrainguinal subset, or 40% of the overall group. How does
this affect the statistical power of this comparison, and would
the same results be seen if a higher prevalence of critical limb
ischemia were studied?
2. Next, you focused on preoperative biomarker values. Why not
follow serial postoperative levels, and what might they add?
With this in mind, did you try to model class prediction
both with and without the biochemical markers to see if
they added signiﬁcant predictive value over use of conven-
tional clinical variables (ie, ankle-brachial index, smoking, clo-
pidogrel, cholesterol/statins, Rutherford score, TransAtlantic
Inter-Society Consensus II grading, diabetes) alone?
3. Last, where do we go from here? As you know, we and
others have also been interested in this line of investigation
and have found CRP to be of limited value. Is it time to
look past CRP, at least for limb-, stent-, or bypass-related
events? Also, can we expect one biomarker to tell the whole
story, or do we need to start thinking about using combina-
tions of markers to create speciﬁc predictive proﬁles that may
have more clinical utility? Say, if we looked at about six
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660 Stone et al September 2014inﬂammatory cytokines that together had strong predictive
value and then created a real-time, point-of-care assay,
should this be the Holy Grail?
I would again like to congratulate Dr Stone on an investigative
strategy that could eventually get us to the point of true “person-
alized medicine” and planning of a treatment strategy based, at
least in part, on preoperative biochemical signatures.
Thanks to the Program Committee for the opportunity to
discuss this important paper.
Dr Patrick A. Stone. I will start with the ﬁrst question on
overall practice and selection bias. The previous chairman of our
department, who was a progressive thinker, advised me to check
high-sensitivity CRP (hsCRP) and BNP levels of all patients preop-
eratively, and this has been a standard outpatient order for me for
more than 5 years. This being said, patients were more commonlyclassiﬁed with claudication compared with critical limb ischemia,
which is a more common inpatient consultation.
I have not checked these biochemical markers serially. One of
the things I am doing now is looking at the patients who return for
repeated interventions (ie, the infrainguinal bypass). When they
come back in for a secondary procedure for vein grafts, stenosis,
and the like, they are coming in for an elective procedure, so they
will have another baseline CRP value to provide more information,
including whether hsCRP predicts future vein graft restenosis.
I think as vascular surgeons we are going to be judged more in
the future on how cost-effective our practice has become. It would
be nice if we could check someone’s hsCRP level and determine
that there is a higher rate of failure with interventions in patients
with elevated hsCRP; then elective procedures should be reconsid-
ered until hsCRP can be improved.
